Form 144: Restricted stock sale notice — Kala Pharmaceuticals (NASDAQ: KALA)
Rhea-AI Filing Summary
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting proposed sales of restricted Common Stock of KALA. The notice lists multiple restricted-stock lots with specific lot sizes and grant/vesting dates, including
The filing lists additional restricted-stock lots (e.g., 397; 1,261; 800; 222; 221; 1,100 shares) tied to grant or restriction dates shown in the table. The filing is a broker notice of proposed sales under Rule 144; timing and aggregate proceeds are not stated in the provided excerpt.
Positive
- None.
Negative
- None.
Insights
Rule 144 notice for proposed resale of restricted shares; procedural compliance is the core action.
The filing lists multiple restricted Common Stock lots for KALA with grant/restriction dates such as
Final sale timing, aggregate amount, and purchaser details are not included in the excerpt; subsequent filings or broker confirmations would show execution and proceeds. Continued compliance with holding‑period and public‑information conditions under Rule 144 will determine whether the sales are permitted.
Administrative resale filing; market impact depends on actual sales, not the notice itself.
The entry lists multiple restricted‑stock lots by date and share count (examples:
Because the form does not state aggregate proceeds or execution method, the economic effect hinges on whether and when the broker executes sales and whether selling holders satisfy holding‑period and public information conditions.
FAQ
What does the KALA Form 144 filing mean?
Which lots of KALA restricted stock are listed on this Form 144?
Does this Form 144 mean the shares have been sold?
Who filed the Form 144 for KALA and what role did they list?